November 23, 2016 - By Peter Kolinski
Valeant Pharmaceuticals International (NYSE:VRX)‘s rating was cut by research professionals at Mizuho from a Neutral rating to a Underperform rating in a research note released on Wednesday, 23 November. The firm after the upgrade has a $11.00 target price per share on the stock. Mizuho’s target price per share means a potential downside of -34.87%.
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 2 “Sell”, while 13 “Hold”. This means 35% are positive. $310 is the highest target while $23 is the lowest. The $107.53 average target is 536.65% above today’s ($16.89) stock price. Valeant Pharmaceuticals Intl has been the topic of 79 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Scotia Capital maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Tuesday, October 20 with “Sector Outperform” rating. Mizuho maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Friday, November 20 with “Buy” rating. The firm has “Hold” rating by Canaccord Genuity given on Wednesday, March 16. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Buy” rating given on Monday, April 11 by Rodman & Renshaw. Nomura downgraded the stock to “Neutral” rating in Wednesday, March 16 report. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Wednesday, October 12 with “Sector Perform” rating. The company was maintained on Wednesday, November 11 by JP Morgan. The firm has “Buy” rating by Bank of America given on Wednesday, September 30. On Wednesday, June 8 the stock rating was maintained by Stifel Nicolaus with “Buy”. JP Morgan downgraded the shares of VRX in a report on Thursday, June 23 to “Neutral” rating.
About 11.10 million shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 46.54% since April 21, 2016 and is downtrending. It has underperformed by 51.87% the S&P500.
Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.02, from 0.86 in 2016Q1. The ratio increased, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Wasatch Advsrs holds 18,238 shares or 0.01% of its portfolio. Cohen Klingenstein Limited last reported 16,738 shares in the company. State Bank Of Nova Scotia accumulated 0.1% or 820,367 shares. Phoenix Invest Adviser Llc holds 1.53% or 82,100 shares in its portfolio. Pictet Asset Management Ltd accumulated 116,800 shares or 0.01% of the stock. Winfield Assocs Inc holds 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 75 shares. Chou Mgmt accumulated 2.66% or 976,843 shares. Marathon Trading Invest Management Ltd holds 28,598 shares or 0.1% of its portfolio. Spot Trading Ltd Liability Corporation holds 0.02% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 56,937 shares. Highfields Cap Management L P reported 250,000 shares or 0.04% of all its holdings. Private Mngmt Gru holds 348,052 shares or 0.46% of its portfolio. Baldwin Brothers Ma accumulated 0% or 250 shares. Acadian Asset Ltd Liability Corp owns 186,884 shares or 0.02% of their US portfolio. Tiaa Cref Investment Management Limited holds 571,468 shares or 0.01% of its portfolio. Parametric Ltd Liability Com has invested 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
Insider Transactions: Since June 9, 2016, the stock had 2 insider buys, and 0 selling transactions for $5.04 million net activity. PAPA JOSEPH C bought $4.94 million worth of stock or 202,000 shares. KARABELAS ARGERIS N had bought 4,000 shares worth $98,600 on Thursday, August 11.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $5.61 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Business.Financialpost.com which released: “Valeant Pharmaceuticals International Inc downgraded again” on November 23, 2016, also Fool.ca with their article: “Will Canopy Growth Corp. Crash as Hard as Valeant Pharmaceuticals Intl Inc.?” published on November 23, 2016, Business.Financialpost.com published: “Valeant Pharmaceuticals International needs to do a lot more than just cry …” on November 21, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Fool.com and their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” with publication date: November 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.